Recombinant human interleukin 15(Beijing Kawin)

重组人白细胞介素15（北京凯因）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human interleukin 15(Beijing Kawin)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin-15 receptor subunit alpha agonistsInterleukin-2 receptor beta chain agonistsInterleukin-2 receptor subunit gamma agonists
TargetsInterleukin-15 receptor subunit alphaInterleukin-2 receptor beta chainInterleukin-2 receptor subunit gamma
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Kawin Technology Share-Holding Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Kawin Technology Share-Holding Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A